CRF Health Launches New ePRO Solution for Data Collection in Late Phase Studies - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
CRF Health Launches New ePRO Solution for Data Collection in Late Phase Studies

Source: Company News Release

The new web-based tool, TrialMax Web, is set to change the way late phase study teams collect patient data by offering a tailor made solution with important patient usability benefits.

  • Enhanced patient focus promotes better engagement, data capture and compliance to generate higher-quality data.
  • The system’s highly intuitive and easy-to-use interface allows data entry via patients’ own computers and/or Smart phones in the “real-world” setting of late phase studies
  • The global solution is fully 21 CFR Part 11 and HIPAA compliant

CRF Health announced the release of an innovative online ePRO and patient management solution for global late phase clinical studies, TrialMax Web. Unique in combining PRO data capture with an array of tools that can improve patient compliance and retention, both critical challenges in late phase research, TrialMax Web has been developed to collect data directly from patients more easily and efficiently than any other web-based solution. TrialMax Web contains unique tools that have been developed and tested in cooperation with patients, patient advocacy groups, and industry outcomes research experts.

Rachael King, CEO, notes: “I am delighted to announce the launch of TrialMax Web, our new solution for late phase study teams. We are proud to offer this exciting patient-focused solution to improve results in late phase studies. We believe that TrialMax Web offers an important new option for global phase IV study teams to interact with patients and deliver the highest quality data.”

TrialMax Web allows late phase studies to collect data from patients without purchasing any hardware, since patients can use it on their own computers or smart phones. As TrialMax Web eliminates the need for handling paper, the collection of Patient Reported Outcomes is more cost efficient and also more easily manageable for large studies. Study teams can utilize the data in real time according to the needs of the study. Recognizing that some study sites involved in late phase studies may lack the experience or resources for managing a study, TrialMax Web provides the reassurance of a tested and proven tool.

“Post-approval research is going through a tremendous change at the moment,” comments King. “We appreciate the challenges of conducting studies in the real-world, and look forward to offering study teams a tool that not only provides them with data, but helps them keep patients connected to the study so they can achieve high quality results.”

TrialMax Web, developed with the help of scientific experts, provides comprehensive capabilities for designing and validating PRO instruments across large patient populations. And because the solution was developed as part of the TrialMax® family of ePRO solutions, the portal is fully inter-operable with all our other components. In addition data can be transferred in real-time to other eClinical systems such as EDC via TrialMax Synapse&™, which means that sponsors can manage their study more efficiently.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here